RIGEL PHARMACEUTICALS INC (RIGL) Form 8-K — Jun 17, 2026
Rigel Pharmaceuticals completed the acquisition of exclusive, global rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant) from a group of licensors including Arvinas and Pfizer.
Key figures
- Deal Value Usd
- 70000000
Price after filing
1 day: -1.4%7 days: +9.5%30 days: +24.9%
Close on the filing date to close N calendar days later (from $33.37). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.